ClinicalTrials.gg
CompletedNCT02719171Updated May 30, 2019Results posted

BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic Arthritis

A Phase 2 interventional study of risankizumab and placebo for risankizumab in Arthritis, Psoriatic, sponsored by AbbVie. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-30.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
185
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Arthritis, Psoriatic by AbbVie — 4 open to participants now, 6 under way, 3 of them phase 3. Arthritis, Psoriatic · AbbVie.

Enrollment
8th of 11
185 · median 246
Started
2016
with 4 others
Phase 2
5 of 34
1 open now
Registered
16th of 34
by date

Among the 34 studies in Arthritis, Psoriatic by AbbVie, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is one of 5 that started in 2016, is one of 5 in phase 2, and was the 16th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

4 of the 34 studies in Arthritis, Psoriatic by AbbVie are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Arthritis, Psoriatic by AbbVie, or all of them as a file.
02

Study summary

The overall purpose of this trial is to assess clinical efficacy and safety of different subcutaneous doses of BI 655066/ABBV-066/risankizumab in adult patients with psoriatic arthritis in order to select doses for further clinical trials.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have psoriatic arthritis (PsA) symptoms for ≥ 6 months prior to screening, as assessed by the investigator
  • Have PsA on the basis of the Classification Criteria for Psoriatic Arthritis (CASPAR) with peripheral symptoms at screening visit, as assessed by the investigator
  • Have ≥ 5 tender joints and ≥ 5 swollen joints at screening and randomisation visits, as assessed by the investigator
  • At least one psoriasis (PsO) lesion or a documented personal history of PsO at screening, as assessed by the investigator
  • If patients receive concurrent PsA treatments, these need to be on stable doses
  • Active PsA that has been inadequately controlled by standard doses of non-steroidal anti-inflammatory drugs (NSAIDs) administered for ≥ 4 weeks, or traditional disease-modifying anti-rheumatic drugs (DMARDs) (including sulfasalazine) administered for ≥ 3 months, or tumor necrosis factor inhibitor (TNFi) agents, or subjects are intolerant to NSAIDs or DMARDs or tumor necrosis factor inhibitor (TNFi) agents, as assessed by the investigator

Exclusion criteria

Exclusion criteria:

  • Major chronic inflammatory or connective tissue disease other than PsA (e.g. rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, Lyme disease, gout) and fibromyalgia, as assessed by the investigator
  • Has received any therapeutic agent directly targeted to interleukin 12/23 (IL-12/23) (including ustekinumab), IL-23 or IL-17 (including secukinumab)
  • Prior use of more than two different TNFi agents
  • Use of the following treatments: TNFi agents within 12 weeks, etanercept within 8 weeks, leflunomide without cholestyramine wash-out within 8 weeks, systemic non-biologic medications for psoriatic arthritis or psoriasis and photochemotherapy within 4 weeks, intraarticular injections (including ) and intramuscular or intravenous corticosteroid treatment within 4 weeks, topical psoriasis medications and phototherapy within 2 weeks, low and high potency opioid analgesics within 2 weeks prior to randomisation
  • Plans for administration of during the study period or within 6 weeks prior to randomisation
  • History of allergy/ to a systemically administered biologic agent or its
  • Active systemic infections during the last 2 weeks (exception: common cold) prior to randomisation, as assessed by the investigator
  • Chronic or relevant acute infections including , viral hepatitis and (or) active tuberculosis (TB). Patients with a positive QuantiFERON TB or purified protein derivate (PPD) test may participate in the study if further work up (according to local practice/guidelines) establishes conclusively that the patient has no evidence of active TB.
  • Any documented active or suspected or history of malignancy within 5 years prior to screening, except appropriately treated basal or squamous cell carcinoma of the skin or in situ carcinoma of uterine cervix
  • Major surgery performed within 12 weeks prior to randomisation or planned within 32 weeks after randomisation (e.g. hip replacement, aneurysm removal, stomach ligation), as assessed by the investigator
  • Total white blood count (WBC) \< 3,000/µL, or \< 100,000/µL or neutrophils \< 1,500/µL, or \< 8.5 g/dL at screening
  • (AST) or alanine aminotransferase (ALT) > 2x the , or serum direct ≥ 1.5 mg/dL at screening
  • Positive rheumatoid factor or anti-cyclic-citrullinated peptide (anti-CCP) antibodies at screening
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
185 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants randomized to receive double-blind (DB) placebo for risankizumab by subcutaneous (SC) injection every 4 weeks for 16 weeks.

    Drug: placebo for risankizumab

  • Experimental
    Risankizumab 150 mg Every 4 Weeks

    Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection every 4 weeks for 16 weeks.

    Drug: risankizumab

  • Experimental
    Risankizumab 150 mg Weeks 0, 4, and 16

    Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0, 4, and 16.

    Drug: risankizumab

  • Experimental
    Risankizumab 150 mg Weeks 0 and 12

    Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 12.

    Drug: risankizumab

  • Experimental
    Risankizumab 75 mg Week 0

    Participants randomized to receive double-blind (DB) risankizumab 75 mg by subcutaneous (SC) injection at Week 0.

    Drug: risankizumab

Interventions

  • Risankizumab administered by SC injection

    Also known as: BI 655066, ABBV-066, SKYRIZI

  • Drugplacebo for risankizumab

    Placebo for risankizumab administered by SC injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16

    Response defined by ACR20 criteria (improvement from baseline) at Week 16: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * Health Assessment Questionnaire Disability Index (HAQ-DI) * Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.

    Time frame: Week 16

Secondary outcomes

  1. Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 16

    Response defined by ACR50 criteria (improvement from baseline) at Week 16: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * HAQ-DI * Acute phase reactant value (C-reactive protein). NRI was used for missing data.

    Time frame: Week 16

  2. Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 16

    Response defined by ACR70 criteria (improvement from baseline) at Week 16: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * HAQ-DI * Acute phase reactant value (C-reactive protein). NRI was used for missing data.

    Time frame: Week 16

  3. Tender Joint Count (TJC68): Change From Baseline to Week 16

    Sixty-eight joints were assessed and classified as either tender (1) or not tender (0). A negative change represents a decrease in the number of tender joints.

    Time frame: Baseline, Week 16

  4. Swollen Joint Count (SJC): Change From Baseline to Week 16

    Sixty-six joints were assessed and classified as either swollen (1) or not swollen (0). A negative change represents a decrease in the number of tender joints.

    Time frame: Baseline, Week 16

  5. Health Assessment Questionnaire Disability Index (HAQ-DI) Score: Change From Baseline to Week 16

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 16

  6. Short Form-36 Health Status Survey (SF-36) Physical Component: Change From Baseline to Week 16

    The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

    Time frame: Baseline, Week 16

  7. SF-36 Mental Component: Change From Baseline to Week 16

    The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

    Time frame: Baseline, Week 16

  8. Dactylitis Count: Change From Baseline to Week 16 in Participants With Dactylitis at Baseline

    The number of fingers and toes with dactylitis (ranging from 0 to 20). A negative change represents a decrease in the number of fingers and toes affected by dactylitis.

    Time frame: Baseline, Week 16

  9. Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Change From Baseline to Week 16 in Participants With Enthesitis at Baseline

    Assessment of enthesitis was performed in the following 16 domains: left and right (L/R) medial epicondyle; L/R lateral epicondyle; L/R supraspinatus insertion into the greater tuberosity of humerus; L/R greater trochanter; L/R quadriceps insertion into superior border of patella; L/R patellar ligament insertion into inferior pole of patella or tibial tubercle; L/R Achilles tendon insertion into calcaneum; L/R plantar fascia insertion into calcaneum. Tenderness at each site was classified as either absent (0) or present (1) to yield total SPARCC scores ranging from 0 (0 sites with tenderness) to 16 (16 sites with tenderness). A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 16

  10. Modified Nail Psoriasis Severity Index (mNAPSI): Change From Baseline to Week 16

    mNAPSI grades each fingernail for onycholysis (separation of the nail plate from the nail bed) and oil-drop (salmon patch) dyschromia (reddish-brown discoloration under the nail plate) on a scale of 0 (none present) to 3 (\>30% of the nail); pitting (small, sharply defined depressions in the nail surface) on a scale of 0 (0 pits present) to 3 (\>50 pits present); nail plate crumbling on a scale of 0 (no crumbling) to 3 (\>50% of nail has crumbling); and presence (1) or absence (0) of leukonychia (white spots), splinter hemorrhages, nail bed hyperkeratosis, and red spots in the lunula. mNAPSI is calculated as the sum of all the components for all of the participants fingernails, for a minimal - maximal total score of 0 to 130. A negative change from Baseline indicates improvement.

    Time frame: Baseline, Week 16

  11. Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16

    PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. The percentage of participants achieving PASI90 at Week 16 are provided. NRI was used for missing data.

    Time frame: Week 16

07

Results

Posted May 30, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0
Started4242423920
Completed4138393718
Not completed14322
Withdrew: Adverse event12002
Withdrew: Lost to follow-up00100
Withdrew: Subject withdrawal02210
Withdrew: Other00010

Outcome measures

PrimaryPercentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16

Response defined by ACR20 criteria (improvement from baseline) at Week 16: ≥ 20% improvement in tender joint count; ≥ 20% improvement in swollen joint count; and ≥ 20% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * Health Assessment Questionnaire Disability Index (HAQ-DI) * Acute phase reactant value (C-reactive protein). Nonresponder imputation (NRI) was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 16
percentage of participantsPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 1635.7 (23.5 to 49.5)57.1 (43.3 to 70.2)61.9 (48.0 to 74.4)59.0 (44.6 to 72.3)65.0 (44.2 to 82.3)59.5 (50.0 to 68.6)60.5 (50.8 to 69.6)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, 16 · Cochran-Mantel-Haenszel · p = 0.007 · Mean difference (final values): 24.0 · 90% CI 9.3 to 38.7
SecondaryPercentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 16

Response defined by ACR50 criteria (improvement from baseline) at Week 16: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * HAQ-DI * Acute phase reactant value (C-reactive protein). NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 16
percentage of participantsPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response at Week 1611.9 (4.8 to 23.4)23.8 (13.5 to 37.0)23.8 (13.5 to 37.0)38.5 (25.4 to 52.9)25.0 (10.4 to 45.6)23.8 (16.4 to 32.7)30.9 (22.5 to 40.4)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · Cochran-Mantel-Haenszel · p = 0.074 · Mean difference (final values): 12.0 · 90% CI 1.0 to 23.0
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · Cochran-Mantel-Haenszel · p = 0.007 · Mean difference (final values): 19.0 · 90% CI 7.4 to 30.6
SecondaryPercentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 16

Response defined by ACR70 criteria (improvement from baseline) at Week 16: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: * Patient assessment of pain * Patient global assessment of disease activity * Investigator's global assessment of disease activity * HAQ-DI * Acute phase reactant value (C-reactive protein). NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 16
percentage of participantsPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 160.0 (0.0 to 6.9)14.3 (6.4 to 26.3)7.1 (2.0 to 17.4)25.6 (14.6 to 39.6)15.0 (4.2 to 34.4)10.7 (5.7 to 18.0)16.0 (9.8 to 24.3)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · Cochran-Mantel-Haenszel · p = 0.006 · Mean difference (final values): 10.3 · 90% CI 4.1 to 16.4
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 15.7 · 90% CI 8.5 to 22.9
SecondaryTender Joint Count (TJC68): Change From Baseline to Week 16

Sixty-eight joints were assessed and classified as either tender (1) or not tender (0). A negative change represents a decrease in the number of tender joints.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · tender joints
Tender Joint Count (TJC68): Change From Baseline to Week 16
tender jointsPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Tender Joint Count (TJC68): Change From Baseline to Week 16-7.9 (-10.6 to -5.2)-7.8 (-10.6 to -5.1)-9.6 (-12.4 to -6.9)-10.4 (-13.2 to -7.5)-10.8 (-14.9 to -6.8)-8.6 (-10.5 to -6.6)-9.9 (-11.8 to -8.0)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · mixed model repeated measures model · p = 0.690 · Mean difference (final values): -0.8 · 90% CI -4.0 to 2.5
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · mixed model repeated measures model · p = 0.260 · Mean difference (final values): -2.1 · 90% CI -5.3 to 1.0
SecondarySwollen Joint Count (SJC): Change From Baseline to Week 16

Sixty-six joints were assessed and classified as either swollen (1) or not swollen (0). A negative change represents a decrease in the number of tender joints.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · swollen joints
Swollen Joint Count (SJC): Change From Baseline to Week 16
swollen jointsPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Swollen Joint Count (SJC): Change From Baseline to Week 16-7.1 (-8.5 to -5.7)-6.8 (-8.3 to -5.4)-7.8 (-9.3 to -6.4)-8.3 (-9.7 to -6.8)-7.8 (-9.9 to -5.7)-7.3 (-8.5 to -6.2)-8.3 (-9.4 to -7.2)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · Cochran-Mantel-Haenszel · p = 0.791 · Mean difference (final values): -0.3 · 90% CI -2.1 to 1.5
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · mixed model repeated measures model · p = 0.320 · Mean difference (final values): -1.1 · 90% CI -2.8 to 0.7
SecondaryHealth Assessment Questionnaire Disability Index (HAQ-DI) Score: Change From Baseline to Week 16

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis that consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 to 3, where 0 represents no disability and 3 very severe, high-dependency disability. HAQ remission indicating normal physical function is defined by HAQ-DI score of \< 0.5. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Health Assessment Questionnaire Disability Index (HAQ-DI) Score: Change From Baseline to Week 16
units on a scalePlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Health Assessment Questionnaire Disability Index (HAQ-DI) Score: Change From Baseline to Week 16-0.089 (-0.204 to 0.026)-0.182 (-0.299 to -0.065)-0.163 (-0.280 to -0.047)-0.245 (-0.365 to -0.126)-0.147 (-0.317 to 0.023)-0.184 (-0.270 to -0.099)-0.206 (-0.291 to -0.120)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · mixed model repeated measures model · p = 0.341 · Mixed model repeated measures model: -0.082 · 90% CI -0.225 to 0.060
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · mixed model repeated measures model · p = 0.181 · Mean difference (final values): -0.114 · 90% CI -0.254 to 0.027
SecondaryShort Form-36 Health Status Survey (SF-36) Physical Component: Change From Baseline to Week 16

The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 1-4 comprise the physical component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Short Form-36 Health Status Survey (SF-36) Physical Component: Change From Baseline to Week 16
units on a scalePlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Short Form-36 Health Status Survey (SF-36) Physical Component: Change From Baseline to Week 161.93 (0.17 to 3.70)3.87 (2.03 to 5.71)3.50 (1.72 to 5.27)3.10 (1.27 to 4.93)7.42 (4.81 to 10.03)3.80 (2.52 to 5.08)3.32 (2.03 to 4.62)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · mixed model repeated measures model · p = 0.174 · Mean difference (final values): 1.70 · 90% CI -0.36 to 3.77
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · mixed model repeated measures model · p = 0.284 · Mean difference (final values): 1.35 · 90% CI -0.73 to 3.44
SecondarySF-36 Mental Component: Change From Baseline to Week 16

The SF-36 determined participant's overall quality of life by assessing 1) limitations in physical functioning due to health problems; 2) limitations in usual role because of physical health problems; 3) bodily pain; 4) general health perceptions; 5) vitality; 6) limitations in social functioning because of physical or emotional problems; 7) limitations in usual role due to emotional problems; and 8) general mental health. Items 5-8 comprise the mental component of the SF-36. Scores on each item were summed and averaged (range = 0-100); a positive change from Baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
SF-36 Mental Component: Change From Baseline to Week 16
units on a scalePlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
SF-36 Mental Component: Change From Baseline to Week 160.48 (-1.74 to 2.69)-0.36 (-2.68 to 1.96)2.26 (0.03 to 4.49)2.84 (0.54 to 5.14)-1.08 (-4.35 to 2.19)1.31 (-0.38 to 3.00)2.29 (0.59 to 3.99)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · mixed model repeated measures model · p = 0.718 · Mean difference (final values): 0.59 · 90% CI -2.12 to 3.30
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · mixed model repeated measures model · p = 0.204 · Mean difference (final values): 2.06 · 90% CI -0.61 to 4.74
SecondaryDactylitis Count: Change From Baseline to Week 16 in Participants With Dactylitis at Baseline

The number of fingers and toes with dactylitis (ranging from 0 to 20). A negative change represents a decrease in the number of fingers and toes affected by dactylitis.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · fingers and toes with dactylitis
Dactylitis Count: Change From Baseline to Week 16 in Participants With Dactylitis at Baseline
fingers and toes with dactylitisPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Dactylitis Count: Change From Baseline to Week 16 in Participants With Dactylitis at Baseline-2.6 (-3.9 to -1.4)-1.1 (-2.2 to 0.1)-1.9 (-3.0 to -0.8)-2.9 (-4.1 to -1.7)-3.5 (-5.2 to -1.8)-1.5 (-2.4 to -0.6)-2.4 (-3.0 to -1.9)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · mixed model repeated measures model · p = 0.243 · Mean difference (final values): 1.2 · 90% CI -0.5 to 2.8
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · mixed model repeated measures model · p = 0.906 · Mean difference (final values): 0.1 · 90% CI -1.0 to 1.1
SecondarySpondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Change From Baseline to Week 16 in Participants With Enthesitis at Baseline

Assessment of enthesitis was performed in the following 16 domains: left and right (L/R) medial epicondyle; L/R lateral epicondyle; L/R supraspinatus insertion into the greater tuberosity of humerus; L/R greater trochanter; L/R quadriceps insertion into superior border of patella; L/R patellar ligament insertion into inferior pole of patella or tibial tubercle; L/R Achilles tendon insertion into calcaneum; L/R plantar fascia insertion into calcaneum. Tenderness at each site was classified as either absent (0) or present (1) to yield total SPARCC scores ranging from 0 (0 sites with tenderness) to 16 (16 sites with tenderness). A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Change From Baseline to Week 16 in Participants With Enthesitis at Baseline
units on a scalePlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index: Change From Baseline to Week 16 in Participants With Enthesitis at Baseline-1.1 (-2.1 to -0.2)-1.4 (-2.3 to -0.5)-2.4 (-3.3 to -1.4)-1.8 (-2.7 to -0.8)-3.7 (-5.1 to -2.3)-1.7 (-2.4 to -1.0)-2.1 (-2.7 to -1.4)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · mixed model repeated measures model · p = 0.325 · Mean difference (final values): -0.7 · 90% CI -1.8 to 0.5
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · mixed model repeated measures model · p = 0.160 · Mean difference (final values): -0.9 · 90% CI -2.1 to 0.2
SecondaryModified Nail Psoriasis Severity Index (mNAPSI): Change From Baseline to Week 16

mNAPSI grades each fingernail for onycholysis (separation of the nail plate from the nail bed) and oil-drop (salmon patch) dyschromia (reddish-brown discoloration under the nail plate) on a scale of 0 (none present) to 3 (\>30% of the nail); pitting (small, sharply defined depressions in the nail surface) on a scale of 0 (0 pits present) to 3 (\>50 pits present); nail plate crumbling on a scale of 0 (no crumbling) to 3 (\>50% of nail has crumbling); and presence (1) or absence (0) of leukonychia (white spots), splinter hemorrhages, nail bed hyperkeratosis, and red spots in the lunula. mNAPSI is calculated as the sum of all the components for all of the participants fingernails, for a minimal - maximal total score of 0 to 130. A negative change from Baseline indicates improvement.

Time frame:
Baseline, Week 16
Reported as:
Least squares mean · units on a scale
Modified Nail Psoriasis Severity Index (mNAPSI): Change From Baseline to Week 16
units on a scalePlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Modified Nail Psoriasis Severity Index (mNAPSI): Change From Baseline to Week 16-5.2 (-7.4 to -3.0)-6.7 (-9.4 to -4.1)-5.8 (-8.2 to -3.4)-10.7 (-13.1 to -8.3)-6.8 (-10.6 to -3.0)-5.5 (-7.3 to -3.8)-8.1 (-9.9 to -6.3)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · mixed model repeated measures model · p = 0.453 · Mean difference (final values): -1.2 · 90% CI -4.0 to 1.5
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · mixed model repeated measures model · p = 0.111 · Mean difference (final values): -2.8 · 90% CI -5.7 to 0.1
SecondaryPercentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16

PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The severity of each sign was assessed using a 5-point scale, where 0=no symptoms, 1=slight, 2=moderate, 3=marked, 4=very marked. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \* 100. The percentage of participants achieving PASI90 at Week 16 are provided. NRI was used for missing data.

Time frame:
Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 16
percentage of participantsPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12
Percentage of Participants Achieving 90% Improvement in Psoriasis Area and Severity Index (PASI) Score (PASI90) at Week 169.5 (1.7 to 27.1)58.3 (31.5 to 81.9)66.7 (44.6 to 84.4)52.2 (33.5 to 70.4)55.6 (25.1 to 83.1)63.3 (46.7 to 77.9)58.5 (44.5 to 71.6)
Statistical analysis
  • Placebo vs Risankizumab 150 mg Every 4 Weeks; 150 mg Weeks 0, 4, and 16 · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 53.5 · 90% CI 35.9 to 71.1
  • Placebo vs Risankizumab 150 mg Weeks 0, 4, and 16; 150 mg Weeks 0 and 12 · Cochran-Mantel-Haenszel · p = <0.001 · Mean difference (final values): 48.8 · 90% CI 33.1 to 64.5

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 15 weeks after the last dose of study drug (up to 31 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/42 (0%)2/42 (4.8%)25/42 (59.5%)
Risankizumab 150 mg Every 4 Weeks0/42 (0%)3/42 (7.1%)16/42 (38.1%)
Risankizumab 150 mg Weeks 0, 4, and 160/42 (0%)0/42 (0%)13/42 (31%)
Risankizumab 150 mg Weeks 0 and 120/39 (0%)2/39 (5.1%)19/39 (48.7%)
Risankizumab 75 mg Week 00/20 (0%)3/20 (15%)13/20 (65%)
Most frequent serious events
Showing 10 of 22
Most frequent serious events
EventPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0
Acute myocardial infarctionCardiac disorders0/420/420/420/391/20
Cardiac failure congestiveCardiac disorders0/420/420/420/391/20
Coronary artery occlusionCardiac disorders0/420/420/420/391/20
Abdominal pain upperGastrointestinal disorders0/420/420/420/391/20
GastroenteritisInfections and infestations0/420/420/420/391/20
InfluenzaInfections and infestations0/420/420/420/391/20
Pyelonephritis acuteInfections and infestations0/420/420/420/391/20
SepsisInfections and infestations0/420/420/420/391/20
Urinary tract infectionInfections and infestations0/420/420/420/391/20
HypoglycaemiaMetabolism and nutrition disorders0/420/420/420/391/20
Most frequent other events
Showing 10 of 27
Most frequent other events
EventPlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0
Viral upper respiratory tract infectionInfections and infestations2/427/425/429/394/20
Upper respiratory tract infectionInfections and infestations5/422/423/422/391/20
HeadacheNervous system disorders3/423/421/423/391/20
FatigueGeneral disorders0/423/421/421/390/20
BronchitisInfections and infestations3/421/421/421/391/20
Pain in extremityMusculoskeletal and connective tissue disorders3/420/420/420/390/20
CoughRespiratory, thoracic and mediastinal disorders2/423/421/421/390/20
PsoriasisSkin and subcutaneous tissue disorders3/421/420/420/390/20
HypertensionVascular disorders3/420/421/421/390/20
Abdominal painGastrointestinal disorders1/420/421/422/390/20

Baseline characteristics

Full Analysis Set (FAS): All randomized participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Total
Mean49.0 ± 11.1651.8 ± 14.5650.1 ± 12.3351.6 ± 11.8753.8 ± 10.9851.0 ± 12.35
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Total
Female182114171080
Male2421282210105
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Total
Hispanic or Latino201003
Not Hispanic or Latino4041393819177
Unknown or Not Reported012115
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRisankizumab 150 mg Every 4 WeeksRisankizumab 150 mg Weeks 0, 4, and 16Risankizumab 150 mg Weeks 0 and 12Risankizumab 75 mg Week 0Total
American Indian or Alaska Native100001
Asian5634422
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White3635373415157
More than one race000000
Unknown or Not Reported012115
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Thakre N, D'Cunha R, Goebel A, Liu W, Pang Y, Suleiman AA. Population Pharmacokinetics and Exposure-Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis. Rheumatol Ther. 2022 Dec;9(6):1587-1603. doi: 10.1007/s40744-022-00495-0. Epub 2022 Sep 30. PubMed 36178584 ↗
  • Mease PJ, Kellner H, Morita A, Kivitz AJ, Aslanyan S, Padula SJ, Topp AS, Eldred A, Behrens F, Papp KA. Long-Term Efficacy and Safety of Risankizumab in Patients with Active Psoriatic Arthritis: Results from a 76-Week Phase 2 Randomized Trial. Rheumatol Ther. 2022 Oct;9(5):1361-1375. doi: 10.1007/s40744-022-00474-5. Epub 2022 Aug 5. PubMed 35931879 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2016 to primary completion in May 2017, 13 months.

Results were first posted in May 2019, 2 years after primary completion. A results delay was requested in Apr 2018.

Of 34 phase 2 interventional studies under Arthritis, Psoriatic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 31. This study's 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2016
First posted
Mar 25, 2016
StartActual
Apr 2016
Primary completionActual
May 2017
CompletionActual
Aug 2017
Results delay requested
Apr 11, 2018
Results first posted
May 30, 2019
Last update
May 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02719171
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 25, 2016
Start date
Apr 2016
Primary completion
May 2017
Completion
Aug 2017
Results posted
May 30, 2019
Last update
May 30, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion